BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BioNexus Gene Lab Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23+0.03 (+2.23%)
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
14.6%−0.5 pts over 5 years
Operating margin
-39.9%−51.1 pts over 5 years
Net margin
-40.2%−49.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -21.9% | -12.1% | -8.2% | – | |
| Gross profit | -15.8% | -4.8% | -8.8% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 28.1% | -35.2% | |
| Return on assets | – | 19.3% | -30.3% | |
| Current ratio | – | 2.37 | 10.46 | |
| Interest coverage | – | – | – | |
| Inventory turnover | – | 16.3× | 6.1× | |
| Capex to revenue | – | 3.7% | 0.5% | |
| Diluted shares | – | 103M | – |
Where the cash went
Fiscal 2021 to 2025, five years combined
BioNexus Gene Lab generated $6.31M from operations and spent $416.52K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$6.31M
Used
$416.52K
Capital expenditure$416.52K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-40.2%
×Asset turnover0.75×
×Equity multiplier1.16×
=Return on equity, FY2025-35.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -40.2% | 0.75× | 1.16× | -35.2% |
| FY2024 | -16.8% | 0.87× | 1.21× | -17.8% |
| FY2023 | -26.9% | 0.97× | 1.23× | -32.2% |
| FY2022 | -3.3% | 1.19× | 1.32× | -5.1% |
| FY2021 | 5.6% | 1.36× | 1.42× | 10.9% |
| FY2020 | 9.6% | 2.01× | 1.46× | 28.1% |
| FY2019 | -194.1% | 0.09× | 1.09× | -18.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$2.98M
- Cash generatingOperating cash flow above zero-$1.84M
- Return on assets improvedROA up on the prior year-14.0% → -28.6%
- Earnings backed by cashOperating cash flow above net income-$1.84M vs -$2.98M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.81 → 10.46
- No dilutionShare count did not rise18M → –
- Gross margin improvedGross margin up on the prior year13.56% → 14.62%
- More efficientAsset turnover rose0.83 → 0.71